Market Overview

The Global Multiple Sclerosis Treatment Market was valued at USD 32,149.8 million in 2023 and is expected to reach USD 44,338.9 million by 2031 while growing at a CAGR of 4.1% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global multiple sclerosis treatment market growth. The goal of multiple sclerosis (MS) treatment is to effectively manage symptoms, decelerate disease progression, and enhance the quality of life for those affected by this chronic autoimmune disorder of the central nervous system.

The increasing prevalence of Multiple Sclerosis, coupled with advancements in biotechnology, neuroimaging, and drug delivery technologies, fuels the Multiple Sclerosis (MS) treatment market. Nonetheless, obstacles like the high cost of treatment and concerns regarding safety and tolerability impede its growth.

Furthermore, the global multiple sclerosis treatment industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Drug Class Analysis

The Global Multiple Sclerosis Treatment Market is segmented among Large-Molecule Drugs, Small-Molecule Drugs, based on Drug Class. In 2023, Large-Molecule Drugs accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Segmentation – By Route of Administration Analysis

The Global Multiple Sclerosis Treatment Market is segmented among Oral, Injectable and Others routes of administration, based on Type. In 2023, Oral accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Multiple Sclerosis Treatment Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Teva Pharmaceuticals Industries Ltd., Novartis AG, Bristol-Myers Squibb Company, Biogen, Bayer AG, Sanofi SA, Viatris Inc. (Mylan NV), Merck KGaA, F. Hoffmann-La Roche AG, Acorda Therapeutics Inc., and Johnson & Johnson.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Multiple Sclerosis Treatment Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Multiple Sclerosis Treatment Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Multiple Sclerosis Treatment Market Segmentation, By Drug Class

• Global Multiple Sclerosis Treatment Market Share Analysis, By Drug Class

• Global Multiple Sclerosis Treatment Market Growth Analysis, By Drug Class

• Global Multiple Sclerosis Treatment Market Trends, By Drug Class

o Large-Molecule Drugs

o Small-Molecule Drugs

6. Global Multiple Sclerosis Treatment Market Segmentation, By Route of Administration

• Global Multiple Sclerosis Treatment Market Share Analysis, By Route of Administration

• Global Multiple Sclerosis Treatment Market Growth Analysis, By Route of Administration

• Global Multiple Sclerosis Treatment Market Trends, By Route of Administration

o Oral

o Injectable and Others routes of administration

7. Global Multiple Sclerosis Treatment Market Segmentation, By Region

• Global Multiple Sclerosis Treatment Market Share Analysis, By Region

• Global Multiple Sclerosis Treatment Market Growth Analysis, By Region

• Global Multiple Sclerosis Treatment Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

8. Competitive Landscape

• Teva Pharmaceuticals Industries Ltd.*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Novartis AG

• Bristol-Myers Squibb Company

• Biogen

• Bayer AG

• Sanofi SA

• Viatris Inc. (Mylan NV)

• Merck KGaA

• F. Hoffmann-La Roche AG

• Acorda Therapeutics Inc.

• Johnson & Johnson

*Similar analysis will be provided for each company listed above.